Therapeutic efficacy of human embryonic stem cell-derived endothelial cells in humanized mouse models harboring a human immune system

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 12, 2013, Pages 2839-2849

  Yang, Heung Mo ^a   Moon, Sung Hwan ^b,c   Choi, Young Sil ^a   Park, Soon Jung ^b,c   Lee, Yong Soo ^a   Lee, Hyun Joo ^a   Kim, Sung Joo ^a   Chung, Hyung Min ^b,c  

^a Samsung Medical Center   (South Korea)

^b Konkuk University School of Medicine   (South Korea)

^c CHA University   (South Korea)

Author keywords

Endothelial cells; Hindlimb ischemia; Human embryonic stem cells; Humanized mouse; Therapeutic efficacy

Indexed keywords

INTERLEUKIN 2 RECEPTOR GAMMA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD; CELL SURVIVAL; CELL THERAPY; CELL TYPE; CONTROLLED STUDY; EMBRYONIC STEM CELL; ENDOTHELIUM CELL; ETHICS; GRAFT REJECTION; HUMAN; HUMAN CELL; IMMUNE SYSTEM; KNOCKOUT MOUSE; LEG ISCHEMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE REGENERATION;

ENDOTHELIAL CELLS; HINDLIMB ISCHEMIA; HUMAN EMBRYONIC STEM CELLS; HUMANIZED MOUSE; THERAPEUTIC EFFICACY;

ANIMALS; BIOLOGICAL MARKERS; CELL LINE; CELL SURVIVAL; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE MODELS, ANIMAL; EMBRYONIC STEM CELLS; ENDOTHELIAL CELLS; FETAL BLOOD; FIBROBLASTS; GRAFT SURVIVAL; HINDLIMB; HUMANS; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED HOST; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; ISCHEMIA; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; MUSCLE, SKELETAL; NEOVASCULARIZATION, PHYSIOLOGIC; RECOVERY OF FUNCTION; REGIONAL BLOOD FLOW; SPECIES SPECIFICITY; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS;

EID: 84888203070     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.113.302462     Document Type: Article

References (38)

1. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282:1145-1147
2. Cho SW, Moon SH, Lee SH, Kang SW, Kim J, Lim JM, Kim HS, Kim BS, Chung HM. Improvement of postnatal neovascularization by human embryonic stem cell derived endothelial-like cell transplantation in a mouse model of hindlimb ischemia. Circulation. 2007;116:2409-2419
3. Moon SH, Kim JS, Park SJ, Lee HJ, Do JT, Chung HM. A system for treating ischemic disease using human embryonic stem cell-derived endothelial cells without direct incorporation. Biomaterials. 2011;32:6445-6455
4. Hagell P, Brundin P. Cell survival and clinical outcome following intrastriatal transplantation in Parkinson disease. J Neuropathol Exp Neurol. 2001;60:741-752
5. Charron D, Suberbielle-Boissel C, Al-Daccak R. Immunogenicity and allogenicity: A challenge of stem cell therapy. J Cardiovasc Transl Res. 2009;2:130-138
6. Saric T, Frenzel LP, Hescheler J. Immunological barriers to embryonic stem cell-derived therapies. Cells Tissues Organs. 2008;188:78-90
7. Drukker M, Katz G, Urbach A, Schuldiner M, Markel G, Itskovitz-Eldor J, Reubinoff B, Mandelboim O, Benvenisty N. Characterization of the expression of MHC proteins in human embryonic stem cells. Proc Natl Acad Sci USA. 2002;99:9864-9869
8. Grinnemo KH, Sylvén C, Hovatta O, Dellgren G, Corbascio M. Immunogenicity of human embryonic stem cells. Cell Tissue Res. 2008;331:67-78
9. Drukker M, Katchman H, Katz G, Even-Tov Friedman S, Shezen E, Hornstein E, Mandelboim O, Reisner Y, Benvenisty N. Human embryonic stem cells and their differentiated derivatives are less susceptible to immune rejection than adult cells. Stem Cells. 2006;24:221-229
10. Li L, Baroja ML, Majumdar A, Chadwick K, Rouleau A, Gallacher L, Ferber I, Lebkowski J, Martin T, Madrenas J, Bhatia M. Human embryonic stem cells possess immune-privileged properties. Stem Cells. 2004;22:448-456
11. Swijnenburg RJ, Schrepfer S, Govaert JA, Cao F, Ransohoff K, Sheikh AY, Haddad M, Connolly AJ, Davis MM, Robbins RC, Wu JC. Immunosuppressive therapy mitigates immunological rejection of human embryonic stem cell xenografts. Proc Natl Acad Sci USA. 2008;105:12991-12996
12. Pearson T, Greiner DL, Shultz LD. Humanized SCID mouse models for biomedical research. Curr Top Microbiol Immunol. 2008;324:25-51
13. Mosier DE, Gulizia RJ, Baird SM, Wilson DB. Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature. 1988;335:256-259
14. Hesselton RM, Greiner DL, Mordes JP, Rajan TV, Sullivan JL, Shultz LD. High levels of human peripheral blood mononuclear cell engraftment and enhanced susceptibility to human immunodeficiency virus type 1 infection in NOD/LtSz-scid/scid mice. J Infect Dis. 1995;172:974-982
15. Hudson WA, Li Q, Le C, Kersey JH. Xenotransplantation of human lymphoid malignancies is optimized in mice with multiple immunologic defects. Leukemia. 1998;12:2029-2033
16. Yaccoby S, Barlogie B, Epstein J. Primary myeloma cells growing in SCID-hu mice: A model for studying the biology and treatment of myeloma and its manifestations. Blood. 1998;92:2908-2913
17. Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, Ueyama Y, Koyanagi Y, Sugamura K, Tsuji K, Heike T, Nakahata T. NOD/ SCID/ gamma©(null) mouse: An excellent recipient mouse model for engraftment of human cells. Blood. 2002;100:3175-3182
18. Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. Nat Rev Immunol. 2007;7:118-130
19. Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J, Homma S, Edwards NM, Itescu S. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med. 2001;7:430-436
20. Kakinuma S, Tanaka Y, Chinzei R, Watanabe M, Shimizu-Saito K, Hara Y, Teramoto K, Arii S, Sato C, Takase K, Yasumizu T, Teraoka H. Human umbilical cord blood as a source of transplantable hepatic progenitor cells. Stem Cells. 2003;21:217-227
21. Li Z, Han Z, Wu JC. Transplantation of human embryonic stem cell-derived endothelial cells for vascular diseases. J Cell Biochem. 2009;106:194-199
22. Park SJ, Moon SH, Lee HJ, Lim JJ, Kim JM, Seo J, Yoo JW, Kim OJ, Kang SW, Chung HM. A comparison of human cord blood-And embryonic stem cell-derived endothelial progenitor cells in the treatment of chronic wounds. Biomaterials. 2013;34:995-1003
23. Murray HW. Interferon-gamma in infection and immunoparalysis. Intensive Care Med. 1996;22(Suppl 4):S455
24. Khandelwal S, Roche PA. Distinct MHC class II molecules are associated on the dendritic cell surface in cholesterol-dependent membrane microdomains. J Biol Chem. 2010;285:35303-35310
25. Harding CV, Geuze HJ. Class II MHC molecules are present in macrophage lysosomes and phagolysosomes that function in the phagocytic processing of Listeria monocytogenes for presentation to T cells. J Cell Biol. 1992;119:531-542
26. Zhang L, Yang R, Han ZC. Transplantation of umbilical cord bloodderived endothelial progenitor cells: A promising method of therapeutic revascularisation. Eur J Haematol. 2006;76:1-8
27. Kim JY, Song SH, Kim KL, Ko JJ, Im JE, Yie SW, Ahn YK, Kim DK, Suh W. Human cord blood-derived endothelial progenitor cells and their conditioned media exhibit therapeutic equivalence for diabetic wound healing. Cell Transplant. 2010;19:1635-1644
28. Toriumi H, Yoshikawa M, Matsuda R, Nishimura F, Yamada S, Hirabayashi H, Nakase H, Nonaka J, Ouji Y, Ishizaka S, Sakaki T. Treatment of Parkinson's disease model mice with allogeneic embryonic stem cells: Necessity of immunosuppressive treatment for sustained improvement. Neurol Res. 2009;31:220-227
29. López MM, Valenzuela JE, Alvarez FC, López-Alvarez MR, Cecilia GS, Paricio PP. Long-Term problems related to immunosuppression. Transpl Immunol. 2006;17:31-35
30. Pearl JI, Lee AS, Leveson-Gower DB, Sun N, Ghosh Z, Lan F, Ransohoff J, Negrin RS, Davis MM, Wu JC. Short-Term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells. Cell Stem Cell. 2011;8:309-317
31. Ljunggren HG, Kärre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today. 1990;11:237-244
32. Suhr ST, Chang EA, Rodriguez RM, Wang K, Ross PJ, Beyhan Z, Murthy S, Cibelli JB. Telomere dynamics in human cells reprogrammed to pluripotency. PLoS One. 2009;4:e8124
33. Tseng HC, Arasteh A, Paranjpe A, Teruel A, Yang W, Behel A, Alva JA, Walter G, Head C, Ishikawa TO, Herschman HR, Cacalano N, Pyle AD, Park NH, Jewett A. Increased lysis of stem cells but not their differentiated cells by natural killer cells; de-differentiation or reprogramming activates NK cells. PLoS One. 2010;5:e11590
34. Lee JE, Kang MS, Park MH, Shim SH, Yoon TK, Chung HM, Lee DR. Evaluation of 28 human embryonic stem cell lines for use as unrelated donors in stem cell therapy: Implications of HLA and ABO genotypes. Cell Transplant. 2010;19:1383-1395
35. Nakajima F, Tokunaga K, Nakatsuji N. Human leukocyte antigen matching estimations in a hypothetical bank of human embryonic stem cell lines in the Japanese population for use in cell transplantation therapy. Stem Cells. 2007;25:983-985
36. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861-872
37. Zhao T, Zhang ZN, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature. 2011;474:212-215
38. Taylor CJ, Bolton EM, Pocock S, Sharples LD, Pedersen RA, Bradley JA. Banking on human embryonic stem cells: Estimating the number of donor cell lines needed for HLA matching. Lancet. 2005;366:2019-2025